NOV-120501

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameNOV-120501
Drug Alias NameBcr-Abl tyrosine kinase modulator (National OncoVenture)NOV-1205NOV-120501
ClassificationSmall molecules
Mechanisms of ActionBcr-Abl tyrosine kinase modulatorsAnticancer protein kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Oncoventure
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Oncoventure
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A